Brief: Almirall And Absci Expand AI Drug Creation Collaboration Adding Second Dermatology Target
07/08/2025 07:04
Aug 7 (Reuters) - Almirall SA ALM.MC: ALMIRALL AND ABSCI EXPAND AI DRUG CREATION COLLABORATION ADDING SECOND DERMATOLOGY TARGET ABSCI ELIGIBLE FOR UP TO $650 MILLION IN PAYMENTS SELECTS SECOND TARGET AIMED AT DERMATOLOGICAL INDICATIONS IN AI DRUG COLLABORATION Source text: ID:nGNXN549D Further company coverage: ALM.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24